Globus Medical's Margin Engine Turns Upward
Q2 2026: Above-market spine growth, a 200bp gross margin step-up, and a deliberate Enabling Tech pivot to drive implant pull-through
GMED · Earnings Call · 2026-08-06
Quarter in focus
Globus Medical delivered an exceptional second quarter that positioned the company for a record 2026. “Q2 revenue was $789.6 million, growing 6% as reported. Excluding Nevro, Q2 revenue growth was 9%, led by 7% U.S. Spine growth and 14% growth in International Spine.” — Keith Pfeil, President and Chief Executive Officer · 2026-08-06 Non-GAAP EPS jumped 56% year-over-year to $1.34, while adjusted EBITDA margin expanded 740 basis points to 35.4%. The strength was broad-based, with Trauma revenue up 31% and competitive recruiting hitting its second-highest onboarding level in eight quarters. The story is no longer just top-line execution; it's about operational leverage. Adjusted gross margin rose to 69.4%, a 200bp improvement, marking the seventh straight quarter of expansion—a clear path toward the mid-70s target. Management reiterated that 2026 gross margin would land in the 69%–70% range and expects to touch the low 70s by year-end, with the mid-70s goal likely in 2027. The operating margin at 20.7% is up 3.3pp year-over-year, reflecting fixed-cost leverage and synergy capture.Enabling Tech: a calculated pivot
One of the most notable strategic shifts is in Enabling Technologies. Revenue declined 26% in Q2, but placements of EGPS and eHub units grew 11% sequentially and 25% versus the prior year. The company is increasingly offering leases and rentals rather than pure cash sales, which suppresses near-term revenue but accelerates pull-through of implants and disposables. As Keith Pfeil explained, “we're looking to get our capital in the hands of our customers to drive implant growth over the long term.” — Keith Pfeil, President and Chief Executive Officer · 2026-08-06 This is a deliberate trade-off—a transition year in which revenue recognition becomes more annuity-like. The global market is watching this theme, as competitors adopt similar flexible models, but Globus is ahead by tying capital placement to its entire procedural ecosystem. The pivot also supports new product vitality. The company launched three products in Q2, including AUTOBAHN Hip fastener and RELINE ONE, and expects to launch the SCRIPT patient-specific lumbar spacers later this quarter. These launches underpin the product development engine that Keith emphasized: "Our team has launched over 25 products over the past 36 months, demonstrating our unwavering focus on organic product development." With over 60 projects in process and R&D spend set to ramp in the back half, the pipeline is full.Nevro: from drag to contributor
The Nevro integration is showing clear signs of traction. While sales declined 14.3% year-over-year, the sequential drop from Q1 was only $1.7 million, and the company expects trial volume recovery by Q4. More remarkably, stand-alone Nevro adjusted EBITDA margin swung from negative 1.4% in the prior year quarter to +22.4% now—a massive improvement driven by cost actions taken in 2025. Kyle Kline noted, "We continue to see the lasting and sustainable impact of cost control actions taken in 2025 on profitability," pointing to the sequential margin expansion. The sales force is being rebuilt, with roughly 75% of open roles filled in Q2, and trial volume is an early indicator of future sales. Management is cautious but confident:This is a classic turnaround in motion—one that could add 100–200bps to consolidated margins as volumes recover.As we get through Q3 and into Q4, our expectation is those trial volumes translate into sales starting to move higher.